Literature DB >> 19787000

Hematology: Thalidomide maintenance in multiple myeloma.

Jacob P Laubach, Paul G Richardson, Kenneth C Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19787000     DOI： 10.1038/nrclinonc.2009.131

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.

Authors:  A Keith Stewart; Christine I Chen; Kang Howson-Jan; Darrell White; Jean Roy; Michael J Kovacs; Chaim Shustik; Anna Sadura; Lois Shepherd; Keyue Ding; Ralph M Meyer; Andrew R Belch
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

2.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  S Vincent Rajkumar; Emily Blood; David Vesole; Rafael Fonseca; Philip R Greipp
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

3.  Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.

Authors:  Michel Attal; Jean-Luc Harousseau; Serge Leyvraz; Chantal Doyen; Cyrille Hulin; Lofti Benboubker; Ibrahim Yakoub Agha; Jean-Henri Bourhis; Laurent Garderet; Brigitte Pegourie; Charles Dumontet; Marc Renaud; Laurent Voillat; Christian Berthou; Gerald Marit; Mathieu Monconduit; Denis Caillot; Bernard Grobois; Herve Avet-Loiseau; Philippe Moreau; Thierry Facon
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

4.  Bone marrow angiogenesis and progression in multiple myeloma.

Authors:  A Vacca; D Ribatti; L Roncali; G Ranieri; G Serio; F Silvestris; F Dammacco
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

5.  Antitumor activity of thalidomide in refractory multiple myeloma.

Authors:  S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

6.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

Authors:  Antonio Palumbo; Sara Bringhen; Tommaso Caravita; Emanuela Merla; Vincenzo Capparella; Vincenzo Callea; Clotilde Cangialosi; Mariella Grasso; Fausto Rossini; Monica Galli; Lucio Catalano; Elena Zamagni; Maria Teresa Petrucci; Valerio De Stefano; Manuela Ceccarelli; Maria Teresa Ambrosini; Ilaria Avonto; Patrizia Falco; Giovannino Ciccone; Anna Marina Liberati; Pellegrino Musto; Mario Boccadoro
Journal:  Lancet       Date:  2006-03-11       Impact factor: 79.321

7.  Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

Authors:  Andrew Spencer; H Miles Prince; Andrew W Roberts; Ian W Prosser; Kenneth F Bradstock; Luke Coyle; Devinder S Gill; Noemi Horvath; John Reynolds; Nola Kennedy
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

8.  Thalidomide is an inhibitor of angiogenesis.

Authors:  R J D'Amato; M S Loughnan; E Flynn; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

Authors:  Bart Barlogie; Guido Tricot; Elias Anaissie; John Shaughnessy; Erik Rasmussen; Frits van Rhee; Athanasios Fassas; Maurizio Zangari; Klaus Hollmig; Mauricio Pineda-Roman; Choon Lee; Giampaolo Talamo; Raymond Thertulien; Elias Kiwan; Somashekar Krishna; Michele Fox; John Crowley
Journal:  N Engl J Med       Date:  2006-03-09       Impact factor: 91.245
  9 in total
  2 in total

1.  Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.

Authors:  Donya Salmasinia; Myron Chang; John R Wingard; Wei Hou; Jan S Moreb
Journal:  Clin Med Insights Oncol       Date:  2010-11-16

Review 2.  Artificial intelligence in COVID-19 drug repurposing.

Authors:  Yadi Zhou; Fei Wang; Jian Tang; Ruth Nussinov; Feixiong Cheng
Journal:  Lancet Digit Health       Date:  2020-09-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.